022-6757-0111
+91-75065-14832
SAIFEE HOSPITAL
Toggle navigation
ABOUT-US
CLINICAL SPECIALITIES
CONTACT
CAREERS
ACADEMICS
ADMIN
Back to Home Page
Medical Oncology & Onco Surgery
Call on : 022-6757-0111 Ext.1236
HEAD OF DEPARTMENT:
DR.MEHBOOB BASADE
SECTION CHIEF:
DR.SANKET MEHTA
(Division of Peritoneal Surface Oncology)
Click on brochure to view
Peritoneal surface malignancies
Research Publications
Adult Neuroblastoma
Genomic Assays In Breast Cancer
Zoledronic Acid Induced Orbital Cellulitis
About Medical Oncology Department
Saifee Hospital treats one of the highest numbers of cancer patients in the city of Mumbai.
State of Art facilities are available for all types of cancer treatment including chemotherapy, immunotherapy and biological therapy.
There are highly trained and specialized chemotherapy resident doctors and nurses.
We also provide Genetic Counseling.
We follow special treatment protocols for treating breast cancer, ovarian cancer in women.
We treat blood cancer (leukamias), lung cancer, colon cancer etc in males.
Variety of genomic analysis on bone marrow tissues are done by the department.
Saifee Hospital is recognized for MUHS Fellowship.
About Onco Surgery
Chemotherapy, immunotherapy, targeted biologic therapy are few of the services available.
We specialize in peritoneal surface malignancies.
We have highly trained professional doctors of International repute on board.
Dedicated nursing staff to manage chemotherapy deliveries, management of long term venous access devices are also available round the clock.
Treatment is avaiable for Cancers of breast, ovaries, colon, stomach, head and neck cancers, lymphomas, leukemias to name a few.
Peritoneal surface malignancies are tumours that either arise from the peritoneum itself or that spread predominantly to and along the peritoneal surface.
CRS and HIPEC
are new treatment techniques developed for the cure of peritoneal surface malignancies.
Read more .....
These kinds of tumours present a rather prickly, therapeutic challenge since the naturally existing blood-peritoneal barrier (a physiological barrier that separates the blood stream and the peritoneal cavity) physically prevents the chemotherapy administered intra-venously from entering the peritoneal cavity in adequate concentrations to be effective at all in eradicating the disease. Further, the disease has a tendency to spread by the phenomenon of Redistribution settling down in areas of stasis and where peritoneal fluid has been reabsorbed. Finally, in patients who are already operated upon, the post-operative adhesions serve as sanctuaries for carcinomatosis (cancerous) cells since chemotherapy cannot reach those areas because of the poor blood-supply post-surgery.
Rationale:
To overcome the above-mentioned challenges, a treatment protocol comprising of a combination of chemotherapy and surgery has been developed in the recent years after several painstaking and systematic experimental and clinical studies. It takes place in 2 stages.
Cyto-Reductive Surgery
Hyperthermic Intra-Peritoneal Chemotheraphy
The Cyto-reductive Maximal Effort Surgery is a procedure that involves systematic, laborious and thorough physical removal of all visible tumour tissue. This, theoretically, reduces a stage IV disease to an RO (no residual tumor status) status with no macroscopic or visible disease. The microscopic disease that may be left behind after such a long surgery is then further eradicated by the HIPEC (Hyperthermic Intra-peritoneal Chemotherapy).
It is the combination of both these modalities that makes this treatment highly effective in the treatment of peritoneal surface malignancies. Now, although this sort of treatment is still advanced and therefore, a novelty, fortunately, the required infrastructure, equipment and more importantly the expertise are all now available. Dr. Sanket Mehta, who has trained in France at one of the pioneering centres for the treatment of peritoneal surface malignancies and colorectal and hepatic diseases, started the first Peritoneal surface malignancy program in Mumbai.